PET/MRI hybrid imaging in the management of CNS tumors: educational exhibit of the usability and advantages shown by a clinical series of diffuse midline glioma (DMG) patients treated with [89Zr]Zr-bevacizumab

摘要

Introduction: PET/MRI combines exquisite structural characterization with non-invasive quantification of target expression and target binding, which can be used to study the potential of drugs to reach (parts of) a tumor, or to determine organs potentially at risk for toxicity (1). To this end, PET/MRI can be used for the selection of the most effective drugs and their most optimal dosage and administration route, and for the selection of patients most likely to benefit from treatment. In this educational exhibit of the first drug imaging study in pediatric brain tumor patients we illustrate the potential of PET/MRI for optimizing the management of tumors located in the brain and nervous system (2).